Intrinsiqq
Grace Therapeutics Inc. logo

Grace Therapeutics Inc. Financials

GRCE

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 8 available years
Income Statement
MAR 2026
~1.4:1 split
MAR 2025
MAR 2024
MAR 2023
MAR 2022
~2.5:1 split
Revenues
Revenue––––$100
Cost of Revenue––––$0
Gross Profit––––$100
Operating Expenses
Selling & Marketing––$0$1$1
General & Administrative$9$7$7$8$9
Research & Development$2$10$5$10$6
Total Operating Expenses––$12$18$15
Operating Income-$11-$17-$13-$52-$16
Non-Operating
Net Interest Expense$1$1$1$0$0
Other Non-Operating Income (Expense)$1$3-$3-$0$5
EBT (Earnings Before Tax)-$9-$13-$15-$52-$10
Income Tax Expense-$2-$3-$2-$10-$1
Net Income
Net Income-$8-$10-$13-$42-$10
Per Share Data
Revenue Per Share––––$16.29
EPS (Basic)-$0.47-$0.79-$1.35-$5.71-$1.62
EPS (Diluted)-$0.47-$0.79-$1.35-$5.71-$1.62
Weighted Avg Shares (Basic)16.5M12.1M9.5M44.6M36.8M
Weighted Avg Shares (Diluted)16.5M12.1M9.5M44.6M36.8M
Shares Outstanding16.5M12.1M9.5M7.4M6.1M

Grace Therapeutics (GRCE) financials: revenue, profit and margins

Grace Therapeutics (GRCE) generated about n/a in revenue and -$21 million in net income over the trailing twelve months, growing at roughly 50,920.4% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Grace Therapeutics profitable?+

Grace Therapeutics reported about -$21 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Grace Therapeutics growing?+

Grace Therapeutics's revenue has compounded at roughly 50,920.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside GRCE's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 11 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.

Fiscal year ends Mar.

Peers

Pharmaceutical Preparations · Pick stocks to compare with GRCE

CompareIntrinsic value
RCUSArcus Biosciences Inc.
$15.62-1.01%10
ASRTAssertio Holdings Inc.
$9.06+0.28%10
SEPNSepterna, Inc.
$38.61-1.51%25
TBPHTheravance Biopharma Inc.
No recent price82
FHTXFoghorn Therapeutics Inc.
$1.72-3.37%46
AMLXAmylyx Pharmaceuticals, Inc.
$26.02-0.69%10
CYTKCytokinetics, Incorporated
$50.78-1.32%18
LFCRLifecore Biomedical, Inc.
$6.39+0.31%21

Spot a number that looks wrong? Check it in GRCE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing GRCE

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.